Search research articles
Contact Us
Filters
Showing results (161-170 of 206) with videos related to
Page
of 21
Sort By:
Scientific Reports
|
October 10, 2018
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence
Helen Pasternack, Jana Fassunke, Patrick Sven Plum, et al.
Plos One
|
May 17, 2011
Benchmarking of mutation diagnostics in clinical lung cancer specimens
Silvia Querings, Janine Altmüller, Sascha Ansén, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2011
Blood-based gene expression signatures in non-small cell lung cancer
Thomas Zander, Andrea Hofmann, Andrea Staratschek-Jox, et al.
JCO Precision Oncology
|
April 20, 2023
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report
Theresa Reutter, Jana Fassunke, Michael Püsken, et al.
Cancer Immunology, Immunotherapy : CII
|
October 2, 2020
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
Katharina Leuchte, Elena Staib, Martin Thelen, et al.
Gut
|
May 24, 2015
Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
Michael Kloth, Vanessa Ruesseler, Christoph Engel, et al.
Oncoimmunology
|
December 15, 2018
B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies
Hans A Schlößer, Martin Thelen, Axel Lechner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
Vincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
Journal for Immunotherapy of Cancer
|
April 17, 2024
Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides
Maria Alejandra Garcia-Marquez, Martin Thelen, Eugen Bauer, et al.
Cancer Research
|
March 3, 2025
Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L Sos, Mirjam Koker, Barbara A Weir, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 206) with videos related to
Sort By:
Page
of 21
Scientific Reports
|
October 10, 2018
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence
Helen Pasternack, Jana Fassunke, Patrick Sven Plum, et al.
Plos One
|
May 17, 2011
Benchmarking of mutation diagnostics in clinical lung cancer specimens
Silvia Querings, Janine Altmüller, Sascha Ansén, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 12, 2011
Blood-based gene expression signatures in non-small cell lung cancer
Thomas Zander, Andrea Hofmann, Andrea Staratschek-Jox, et al.
JCO Precision Oncology
|
April 20, 2023
Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report
Theresa Reutter, Jana Fassunke, Michael Püsken, et al.
Cancer Immunology, Immunotherapy : CII
|
October 2, 2020
Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
Katharina Leuchte, Elena Staib, Martin Thelen, et al.
Gut
|
May 24, 2015
Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
Michael Kloth, Vanessa Ruesseler, Christoph Engel, et al.
Oncoimmunology
|
December 15, 2018
B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies
Hans A Schlößer, Martin Thelen, Axel Lechner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 10, 2025
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
Vincent Ribrag, Lara Iglesias, Filippo De Braud, et al.
Journal for Immunotherapy of Cancer
|
April 17, 2024
Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides
Maria Alejandra Garcia-Marquez, Martin Thelen, Eugen Bauer, et al.
Cancer Research
|
March 3, 2025
Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L Sos, Mirjam Koker, Barbara A Weir, et al.
Page
of 21